Document:

Exhibit 10.4

 

contribution
AND SUBSCRIPTION AGREEMENT

 

THIS
CONTRIBUTION AND SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of this 24th day of January,
2018 by and between Lung Therapeutics, Inc., a Texas corporation (the “Contributor”),
and TFF Pharmaceuticals, Inc., a Delaware corporation (the “Company”).

 

R E C I T A L S

 

A. The
Company desires to acquire certain assets of the Contributor related to its Thin Film Freezing (TFF) process (collectively, the
“TFF Assets”).

 

B. Subject
to the terms and conditions of this Agreement, the Contributor desires to contribute the TFF Assets to the Company in exchange
for 4,000,000 shares (the “Shares”) of the common stock of the Company, $0.001 par value per share (the
“Common Stock”).

 

NOW, THEREFORE,
in consideration of the mutual premises herein made, and in consideration of the representations, warranties and covenants herein
contained, the parties hereto agree as follows:

 

SECTION 1: Contribution
and Subscription. On the terms and subject to the conditions set forth in this Agreement, the Contributor hereby agrees
to contribute, transfer, assign and deliver to the Company, and the Company hereby accepts the contribution, transfer and
assignment from the Contributor, the TFF Assets described below in exchange for the Company’s issuance of the Shares to
the Contributor.

 

(a) TFF
Asset Contribution. The Contributor hereby contributes, transfers, assigns, conveys and delivers to the Company, free and clear
of all liens, claims, security interests or other encumbrances, the TFF Assets, as more specifically described below:

 

		(1)	The Patent License Agreement No. PM1504101, dated as
of July 8, 2015, by and between the Contributor and The University of Texas at Austin (the “PLA”),
it being understood that the Company will be responsible for any payments required by The University of Texas at Austin with respect
to an assignment of the PLA;

 

		(2)	The Master Services Agreement, dated as of August 31, 2015, by and between
the Contributor and Hovione Inter Limited, a Swiss company (the “MSA”);

 

		(3)	All intellectual property and intellectual property rights that are owned or
controlled by the Contributor that are or were used in, necessary for the conduct of, or related to, the PLA or the MSA, together
with the goodwill associated with the PLA and the MSA;

 

		(4)	All sponsored research and associated reports, data, materials, books and records
relating to the PLA or the MSA;

 

		(5)	All books, records, files, data, customer lists, customer records, research
and development reports and advertising and promotional materials that relate to the PLA and the MSA; and

 

		(6)	The equipment specified on Appendix A attached hereto.

 

     

     

    

 

(b) Excluded
Assets. Except for the TFF Assets, the Company shall not acquire, and the Contributor shall retain, all remaining assets of
the Contributor.

 

(c) Assumed
Liabilities. The Company agrees to assume and be responsible for all liabilities and obligations arising on or after the date
hereof associated with the Company’s use, ownership or operation of the TFF Assets (the “Assumed Liabilities”).

 

(d) Excluded
Liabilities. Other than the Assumed Liabilities, the Company shall not assume any liabilities or obligations of the Contributor
of any kind, whether known or unknown, contingent, matured or otherwise, whether currently existing or hereinafter created.

 

SECTION 2: Representations
and Warranties. The Parties each have the requisite power and authority to, and have each obtained all necessary corporate
approvals, as applicable, to execute and deliver this Agreement, to carry out its obligations hereunder, and to consummate the
transactions contemplated hereby.

 

SECTION 3: Assignment.
This Agreement shall constitute the “General Assignment” of the assets and rights contributed hereunder, and the Contributor
hereby transfers, grants, and assigns to the Company the Contributor’s entire right, title, and interest in and to the TTF
Assets.

 

SECTION 4: Lock-Up.

 

(a) General.
The Contributor agrees that, during the period beginning on and including the close of an initial public offering of the Common
Stock (“Effective Date”) through and including the twelve-month anniversary of the Effective Date (the
“Lock-Up Period”), the Contributor, or any affiliated party of the Contributor, will not, without the
prior written consent of the Company, directly or indirectly:

 

		(1)	offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose
of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, whether now owned
or hereafter acquired by the undersigned or with respect to which the Founder has or hereafter acquires the power of disposition,
or

 

		(2)	enter into any swap or other agreement, arrangement or transaction that transfers
to another, in whole or in part, directly or indirectly, any of the economic consequence of ownership of any shares of Common Stock
or any securities convertible into or exercisable or exchangeable for any Common Stock, whether any transaction described in clause (a)
or (b) above is to be settled by delivery of Common Stock, other securities, in cash or otherwise.

 

    2

     

    

 

(b) Limited
Exception. Notwithstanding the provisions set forth in Section 4(a), the Contributor may, without the prior written consent
of the Company, transfer any shares of Common Stock acquired in an open market purchase following the Effective Date.

 

SECTION 5: Tax Treatment of Contribution.
The Parties hereto acknowledge that the Contributor’s transfer of the TFF Assets to the Company and the Company’s issuance
of the Shares to the Contributor will close concurrent with those transactions under that certain Securities Purchase Agreement
(the “Purchase Agreement”) to be entered into by and among the Company and certain investors, all of
which shall constitute a single integrated plan intended to qualify as a tax-free transaction under Section 351 of the Internal
Revenue Code of 1986, as amended. The Parties further agree that each of them will report all such transactions in a manner consistent
with such qualification.

 

SECTION 6: Closing. The closing
of the transactions contemplated by this Agreement (the “Closing”) shall take place at the offices of
Greenberg Traurig, LLP, 3161 Michelson Drive, Suite 1000, Irvine, California 92612, commencing concurrently with the Initial Closing
(as defined in the Purchase Agreement).

 

SECTION 7: Further Assurances.
Each party shall perform such acts, execute and deliver such instruments and documents, and do all such things as reasonably necessary
to accomplish the transactions contemplated in this Agreement and/or otherwise give effect to this Agreement, including but not
limited to any consents or assignments required to assign the PLA.

 

SECTION 8: Miscellaneous.

 

(a) Amendments
and Waivers. Except as otherwise provided herein, no modification, amendment or waiver of any provision hereof shall be effective
against the parties unless such modification, amendment or waiver is approved in writing by each party against whom such modification,
agreement or waiver is to apply. The failure of any party to enforce any provision of this Agreement or under any agreement shall
in no way be construed as a waiver of such provisions and shall not affect the right of such party thereafter to enforce each and
every provision of this Agreement.

 

(b) Successors
and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by the Parties and their respective
successors and assigns.

 

(c) Severability.
Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable under any applicable law or rule in
any jurisdiction, such provision will be ineffective only to the extent of such invalidity, illegality or unenforceability in such
jurisdiction, without invalidating the remainder of this Agreement in such jurisdiction or any provision hereof in any other jurisdiction.

 

(d) Counterparts.
This Agreement may be executed simultaneously in two or more counterparts, any one of which need not contain the signatures of
more than one party, by all such counterparts taken together will constitute one and the same Agreement.

 

(e) Descriptive
Headings. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a part of this
Agreement.

 

(f) Complete
Agreement. This Agreement embodies the complete agreement and understanding among the parties and supersedes and preempts any
prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject
matter hereof in any way.

 

(g) Governing
Law. All issues concerning the enforceability, validity and binding effect of this Agreement shall be governed by and construed
in accordance with the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or
rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the law of any jurisdiction
other than the State of Delaware.

 

* * *

 

    3

     

    

 

IN WITNESS WHEREOF, the parties hereto have executed this Contribution
Agreement on the date and year first above written:

 

	 	LUNG THERAPEUTICS, INC.,
	 	a Texas corporation
	 	 	 
	 	By:	/s/ Brian Windsor
	 	Name: 	Brian Windsor
	 	Title: 	Chief Executive Officer
	 	 	 
	 	TFF PHARMACEUTICALS, INC., 
	 	a Delaware corporation
	 	 	 
	 	By:	/s/ Robert S. Mills
	 	Name: 	Robert S. Mills, Jr.
	 	Title: 	Chief Executive Officer

 

     

     

    

 

Appendix A

 

One (1) Freezer Cylinder Apparatus and Cage

One (1) AdVantage Pro lyophilizerExhibit 10.5

 

Patent License Agreement

Agreement No. PM1504101

 

This Patent License Agreement is between the Licensor and the
Licensee identified below (collectively, “Parties”, or singly, “Party”).

 

No binding agreement between the Parties will exist until
this Patent License Agreement has been signed by both Parties. Unsigned drafts of this Patent License Agreement shall not be considered
offers.

 

Background

 

Licensor owns or controls Patent Rights. Licensee desires to
secure the right and license to use, develop, manufacture, market, and commercialize the Patent Rights. Licensor has determined
that such use, development, and commercialization of the Patent Rights is in the public’s best interest and is consistent
with Licensor’s educational and research missions and goals. Licensor desires to have the Patent Rights developed and used
for the benefit of Licensee, the inventors, Licensor, and the public.

 

Certain Patent Rights covered by the Patent License Agreement
were assigned to Board of Regents of the University of Texas System by Dow Global Technologies Inc.

 

The University of Texas at Austin, on behalf of the Board of
Regents of the University of Texas System, has entered an Inter-Institutional Agreement with The University of Texas Health and
Science Center San Antonio to provide The University of Texas at Austin rights to license certain jointly owned Patent Rights covered
by the Patent License Agreement.

 

NOW, THEREFORE, in consideration of the mutual covenants and
premises herein contained, the Parties hereby agree as follows:

 

The Terms and Conditions of Patent License attached hereto as
Exhibit A are incorporated herein by reference in their entirety (the “Terms and Conditions”). In the event of a conflict
between provisions of this Patent License Agreement and the Terms and Conditions, the provisions in this Patent License Agreement
shall govern. Unless defined in this Patent License Agreement, capitalized terms used in this Patent License Agreement shall have
the meanings given to them in the Terms and Conditions.

 

The section numbers used in the left hand column in the table
below correspond to the section numbers in the Terms and Conditions.

 

	1.    Definitions
	 	Effective Date	Date of last signature below.
	 	Licensor	The University of Texas at Austin, on behalf of the Board of Regents of the University of Texas System, an agency of the State of Texas, whose address is 3925 W. Braker Lane, Suite 1.9A (R3500), Austin, Texas 78759.

 

     

     

    

 

	 	Licensee	Lung Therapeutics, Inc., a Texas corporation, with its principal place of business at 7500 Rialto Boulevard, Ste. 250, Austin, Texas 78735
	 	Contract Year and Contract Quarters	
        (Check one box to correspond with Licensee fiscal year and quarters)

         

         ̈Contract
        Year is 12-month period ending on December 31 and Contract Quarters are 3-month periods ending on March 31, June 30, Sept. 30,
        Dec. 31.

        OR

         ̈ Other: Contract Year is 12-month period ending on (specify):
        [month and day]; Contract Quarters are 3-month periods ending on (specify): [month and day, Q1], [month and day, Q2], [month and
        day, Q3], [month and day, Q4]

	 	Territory	Worldwide
	 	Field	
        “Exclusive Field” for Patent Rights listed
        in Exhibit B

        “Limited Exclusive Field” for Patent Rights
        listed in Exhibit C

	 	Patent Rights	See Exhibit B “Exclusive Patent Rights” and Exhibit C “Limited Exclusive Patent Rights”
	 	USPTO Entity Status as of Effective Date	Check one box:

 ̈ Small

 ̈ Large
	2.4.    Diligence Milestones
	 	Milestones and deadlines	Milestone Events	Deadlines
	1. Before the first anniversary of the Effective Date, Licensee shall provide a detailed commercialization plan that must include a financing plan, and a timeline for bringing the first indication to market, including clinical trials and regulatory approval, plans for developing thin film freezing as a platform for clinical grade manufacturing, and plans for developing products or methods related to each of the Licensed Patents.  Such commercialization plan must meet Licensor’s approval and such approval shall not be unreasonably withheld.  The Patent License Agreement will be amended by mutual agreement to insert commercial diligence milestones based on this commercialization plan.	First anniversary of Effective Date.

 

    	 	2	 

     

    

 

	3.    Compensation
	3.1(a)	Patent expenses due on first anniversary of Effective Date subject to Sections 3.1(a), 6.1 and 6.5 in Terms and Conditions, and Special Provision 20.1	Amount and due date	Based on invoices

 received as of:
	$235,187.98	May 18, 2015
	3.1(b)	Milestone fees	Milestone Events	Milestone Fees
	1.    Submit IND (or foreign equivalent) on a first indication for a Licensed Product	$100,000
	2.    Initiation of Phase II clinical trial (or foreign equivalent) on a first indication for a Licensed Product	$200,000
	3.    Initiation of Phase III clinical trial (or foreign equivalent) on a first indication for a Licensed Product	$500,000
	4.    Regulatory Approval in US (or foreign equivalent) on a first indication for a Licensed Product	$500,000
	5.    FDA Granted Orphan Exclusivity Period	As set forth in Special Provision 202
	3.1(c)	Scheduled license fee payments	$5,000 due on December 31, 2018 for the 2018 Contract Year $15,000 due on December 31 for each Contract Year thereafter

 

    	 	3	 

     

    

 

	3.1(d)	Sublicense Fees	
        40% of Non-Royalty Sublicensing Consideration from a Sublicense
        Agreement executed prior to submission of IND (or foreign equivalent);

         

        25% of Non-Royalty Sublicensing Consideration from a Sublicense
        Agreement executed after IND submission but prior to initiation of Phase I clinical trial (or foreign equivalent);

         

        15% of Non-Royalty Sublicensing Consideration from a Sublicense
        Agreement executed after initiation of Phase I clinical trial (or foreign equivalent), but prior to initiation of Phase II clinical
        trial (or foreign equivalent);

         

        10% of Non-Royalty Sublicensing Consideration from a Sublicense
        Agreement executed after initiation of Phase II clinical trial (or foreign equivalent), but prior to initiation of Phase III clinical
        trial (or foreign equivalent);

         

        7.5% of Non-Royalty Sublicensing Consideration from a Sublicense
        Agreement executed after initiation of Phase III clinical trial (or foreign equivalent), or first sale whichever comes earlier.

	3.1(e)	Assignment fee	$100,000
	3.1(f)	FDA Priority Review Voucher	25%
	3.2	Running royalty rate (applies to Net Sales by Licensee, Affiliates and Sublicensees)	2%
	18.    Contact Information
	 	Licensee Contacts	Licensor Contacts
	 	
        Contact for Notice:

        Attn: Brian Windsor

        7500 Rialto Boulevard, Ste. 250

        Austin, Texas 78735

        Phone: 512.872.7527

        E-mail: bwindsor@lungtx.com

         

        Accounting contact:

        Attn: Brian Windsor

        7500 Rialto Boulevard, Ste. 250

        Austin, Texas 78735

        Phone: 512.872.7527

        E-mail: bwindsor@lungtx.com
	
        Contact for Notice:

        Attn: Contract Manager

        3925 W. Braker Lane, Suite 1.9A (R3500)

        Austin, TX 78759

        Fax: 512.475.6894

        Phone: 512.471.2995

        E-mail: licensing@otc.utexas.edu

         

        Payment and reporting contact:

        Checks payable to “The University of Texas at Austin”

	 	 	 	 

 

    	 	4	 

     

    

 

	 	
        Patent prosecution contact:

        Attn: Brian Windsor

        7500 Rialto Boulevard, Ste. 250

        Austin, Texas 78735

        Phone: 512.872.7527

        E-mail: bwindsor@lungtx.com
	
        Attn: Accounting

        3925 W. Braker Lane, Suite 1.9A (R3500)

        Austin, TX 78759

        Fax: 512.475.6894

        Phone: 512.471.2995

        E-mail: accounting@otc.utexas.edu

         

        Patent prosecution contact:

        Attn: Patents

        3925 W. Braker Lane, Suite 1.9A (R3500)

        Austin, TX 78759

        Fax: 512.475.6894

        Phone: 512.471.2995

        E-mail: patents@otc.utexas.edu

	For Licensor Administrative Purposes Only
	Changes to Standard Form Terms and Conditions	1, 2.1, 2.3, 3,1, 3.2, 3.3, 3.4, 6.1, 6.5, 6.7, 9.1, 9.2, 20.1, 20.2
	 	 	 	 

 

20.         Special Provision.
The Parties hereby agree to the following special provisions set forth in this Section 20 with respect to this Patent License Agreement.

 

20.1       Past Patent
Cost Reimbursement Opt Out Period

 

Licensee shall pay past patent expenses as set forth in Section
3.1(a) of the Terms and conditions, except that if Licensee elects to withdraw from paying patent costs for any particular Patent
Rights as set forth in Section 6.5 of the Terms and Conditions before the first anniversary of the Effective Date, then Licensee
shall not be required to pay the past patent expenses for such withdrawn Patent Rights. For the sake of clarity, the amount due
at the first anniversary of the Effective Date shall survive termination.

 

20.2       FDA Granted
Orphan Exclusivity Period Milestone Fee

 

If any drug is granted orphan designation by the FDA (e.g.,
as described in 21 CFR § 316) while that drug is a Licensed Product, then Licensee shall pay Licensor $9,625,000 (the “FDA
Granted Orphan Exclusivity Period Milestone Fee”). Such amount will be paid to Licensor in two payments; the first payment
of $875,000 is due when cumulative sales (less deductions otherwise specifically allowed in the definition of Net Product Sales)
of the approved orphan drug in the territory in which Licensor is granted exclusivity by such designation (the “FDA Granted
Orphan Exclusivity Territory”) reach $50,000,000 during the term of the exclusivity granted in such designation (the “Orphan
Drug Exclusivity Term”); the second payment of $8,750,000 is due when cumulative sales of such orphan drug in the FDA Granted
Orphan Exclusivity Territory reach $500,000,000 during the Orphan Drug Exclusivity Term. For the sake of clarity, payments shall
be due only if the orphan drug has applicable sales in the FDA Granted Orphan Exclusivity Territory during the Orphan Drug Exclusivity
Term.

 

    	 	5	 

     

    

 

Royalties paid to Licensor from the sales of said orphan drug
in the FDA Granted Orphan Exclusivity Territory may be credited once against a FDA Granted Orphan Exclusivity Period Milestone
Fee payment. For example, if the orphan drug reaches $500,000,000 in cumulative sales in the FDA Granted Orphan Exclusivity Territory,
and $750,000 in associated royalties were paid to Licensor, then such paid royalties may be credited against FDA Granted Orphan
Exclusivity Period Milestone Fee, and $8,000,000 of the $8,750,000 payment would be due. Licensee’s obligation to pay the
FDA Granted Orphan Exclusivity Period Milestone Fee shall survive Termination, but only apply during Orphan Drug Exclusivity Term.
For the sake of clarity, if cumulative sales in the FDA Granted Orphan Exclusivity Territory reached $50,000,000, but $1,000 of
the $50,000,000 in sales occurred after the Orphan Drug Exclusivity Term ended, then $0 of the $875,000 first payment would be
due. For the sake of further clarity, the FDA Granted Orphan Exclusivity Period Milestone Fee shall be due for any and all drugs
that are granted orphan designation by the FDA while those drugs are a Licensed Product, regardless of the prior payment of such
fee for a different drug.

 

21.         No Other
Promises and Agreements; Representation by Counsel. Licensee expressly warrants and represents and does hereby state and
represent that no promise or agreement which is not herein expressed has been made to Licensee in executing this Patent License
Agreement except those explicitly set forth herein and in the Terms and Conditions, and that Licensee is not relying upon any statement
or representation of Licensor or its representatives. Licensee is relying on Licensee’s own judgment and has had the opportunity
to be represented by legal counsel. Licensee hereby warrants and represents that Licensee understands and agrees to all terms and
conditions set forth in this Patent License Agreement and said Terms and Conditions.

 

22.         Deadline
for Execution by Licensee. If this Patent License Agreement is executed first by the Licensor and is not executed by the
Licensee and received by the Licensor at the address and in the manner set forth in Section 18 of the Terms and Conditions within
30 days of the date of signature set forth under the Licensor’s signature below, then this Patent License Agreement shall
be null and void and of no further effect.

 

    	 	6	 

     

    

 

IN WITNESS WHEREOF, the Parties hereto have caused their duly
authorized representatives to execute this Patent License Agreement.

 

	LICENSOR: THE UNIVERSITY OF TEXAS AT AUSTIN ON BEHALF OF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM	 	LICENSEE: Lung Therapeutics, Inc.
	 	 	 	 	 
	By:	/s/ Daniel W. Sharp	 	By:	/s/ Brian Windsor
	 	 	 	 	 
	Daniel W. Sharp, J.D.	 	Brian Windsor
	 	 	 
	Associate Vice President for Research and Director, Office of Technology Commercialization	 	CEO
	 	 	 
	Date:	July 8, 2015	 	Date:	July 8, 2015

 

    	 	7	 

     

    

 

EXHIBIT A

Terms and Conditions of Patent License

 

These Terms and Conditions of Patent License (“Terms and
Conditions”) are incorporated by reference into the Patent License Agreement to which they are attached. All Section references
in these Terms and Conditions shall be references to provisions in these Terms and Conditions unless explicitly stated otherwise.

 

		1.	Definitions

 

“Affiliate” means any business
entity more than 50% owned by Licensee, any business entity which owns more than 50% of Licensee, or any business entity that is
more than 50% owned by a business entity that owns more than 50% of Licensee.

 

“Agreement” means collectively
(i) these Terms and Conditions, and (ii) the Patent License Agreement.

 

“Contract Quarter” means the three-month
periods indicated as the contract Quarter in Section 1 of the Patent License Agreement, or any stub period thereof at the commencement
of the Agreement or the expiration or termination of the Agreement.

 

“Contract Year” means the 12-month
periods indicated as the Contract Year in Section 1 of the Patent License Agreement, or any stub period thereof at the commencement
of the Agreement or the expiration or termination of the Agreement.

 

“Effective Date” means the date
indicated as the Effective Date in Section 1 of the Patent License Agreement.

 

“Exclusive Field” means all fields.

 

“Fair Market Value” means the cash
consideration an unaffiliated, unrelated buyer would pay in an arm’s length sale of a substantially identical item sold in
the same quantity, under the same terms, and at the same time and place.

 

“Field” means Limited Exclusive
Field and/or Exclusive Field, as appropriate.

 

“Government” means any agency,
department or other unit of the United States of America or the State of Texas.

 

“Gross Consideration” means all
cash and non-cash consideration (e.g., securities).

 

“Licensed Process” means a method
or process whose practice or use is covered by a Valid Claim.

 

“Licensed Product” means any product
or component (i) whose manufacture, use, sale, offer for sale or import is covered by any Valid Claim, or (ii) which is made using
a Licensed Process or another Licensed Product.

 

    	 	8	 

     

    

 

“Licensed Service” means performance
of a service for any consideration using a Licensed Product, or the practice of a Licensed Process. For clarity, research and development
of Licensed Products by Licensee, its Affiliates, or a Sublicensee does not constitute a Licensed Service.

 

“Licensee” means the Party identified
as the Licensee in Section 1 of the Patent License Agreement.

 

“Licensor” means the Party identified
as the Licensor in Section 1 of the Patent License Agreement.

 

“Limited Exclusive Field” means
all fields except for the field of vaccines.

 

“Milestone Fees” means all fees
identified as Milestone Fees in Section 3.1(b) of the Patent License Agreement.

 

“Net Product Sales” means the Gross
Consideration from the Sale of Licensed Products less the following items directly attributable to the Sale of such Licensed Products
that are specifically identified on the invoice for such Sale and borne by the Licensee, Affiliates, or Sublicensees as the seller:
(a) discounts and rebates actually granted; (b) sales, value added, use and other taxes and government charges actually paid, excluding
income taxes; (c) import and export duties actually paid; (d) freight, transport, packing and transit insurance charges actually
paid or allowed; and (e) other amounts actually refunded, allowed or credited due to rejections or returns, but not exceeding the
original invoiced amount.

 

Additionally, if Licensee, its Affiliates or Sublicensees
use a Licensed Product or a Licensed Process for its own internal purposes or otherwise in a situation that does not involve a
Sale for which a royalty is paid under Section 3.2, then Net Product Sales shall also include an amount equal to the customary
sale price charged to a third party for the same Licensed Product or Licensed Process, except for a reasonable quantity used internally
solely for testing or quality control purposes, marketing or demonstration purposes, or seeking governmental approval (e.g., U.S.
Food and Drug Administration clinical trial). If there is no customary sale price, then the Net Product Sales shall be an amount
equal to the Fair Market Value.

 

“Net Sales” means the total of
Net Product Sales and Net Service Sales.

 

“Net Service Sales” means the Gross
Consideration received from the Sale of Licensed Services less the following items, directly attributable to the Sale of such Licensed
Services that are specifically identified on the invoice for such Sale and borne by the Licensee, Affiliates, or Sublicensees as
the seller: (a) discounts and rebates actually granted; (b) sales, value added, use and other taxes and government charges actually
paid, excluding income taxes; and (c) other amounts actually refunded, allowed or credited due to rejections or re-works, but not
exceeding the original invoiced amount.

 

    	 	9	 

     

    

 

“Non-Royalty Sublicensing Consideration”
means the Gross Consideration received by the Licensee or its Affiliate from a Sublicensee in consideration of the grant of a sublicense
under the Patent Rights (including, without limitation, license or option or distribution fees, fees to maintain license rights,
and bonus/milestone payments), but excluding amounts received as running royalties, a profit share, or other revenue sharing based
on Net Product Sales or Net Service Sales for which Licensor receives a running royalty under Section 3.2. For the avoidance of
doubt, Non-Royalty Sublicensing Consideration shall not include bona fide: (a) running royalties received by Licensee or an Affiliate
based on Net Product Sales or Net Service Sales that are royalty-bearing to Licensor under Section 3.2, (b) purchase price for
Licensee’s stock or other securities not in excess of Fair Market Value, and (iii) amounts paid and used exclusively for
research and development of Licensed Products or Licensed Services by Licensee.

 

“Orphan Drug Exclusivity Term”
means the time period described in 21 CFR § 316.31 when no other sponsor’s marketing application for the same drug for
the same use or indication will be approved.

 

“Patent License Agreement” means
the particular Patent License Agreement to which these Terms and Conditions are attached and incorporated into by reference.

 

“Patent Rights” means the Licensor’s
rights in (a) the patents and patent applications listed in Section 1 of the Patent License Agreement; (b) all non-provisional
patent applications that claim priority to any provisional application listed in Section 1 of the Patent License Agreement; and
(c) all divisionals, continuations, and such claims of continuations-in-part as are entitled to claim priority to the aforesaid
patents and/or patent applications, and all reissues, reexaminations, extensions of, and foreign counterparts; and (d) any patents
that issue with respect to the aforesaid patent applications. From time to time during the term of the Agreement, upon written
agreement by both parties, Licensee and Licensor shall update the list of all patent applications and patents within the Patent
Rights.

 

“Phase I” means a human clinical
trial of a Licensed Product, including the initial introduction into humans, the principal purpose of which is to obtain sufficient
information about the Product’s pharmacokinetics and pharmacological effects to permit the design of further clinical trials,
and be generally consistent with 21 CFR § 312.21(a). Said trial may be conducted in any country.

 

“Phase II” means a human clinical
trial of a Licensed Product the principal purpose of which is to make a preliminary determination that such Product is safe in
a patient population for its intended use and to obtain sufficient information about such Product’s efficacy to permit the
design of further clinical trials, and be generally consistent with 21 CFR § 312.21(b). Said trial may be conducted in any
country.

 

“Phase M” means a human clinical
trial of a Licensed Product, which trial is designed to: (a) establish that a Licensed Product is safe and efficacious for its
intended use; (b) define warnings, precautions and adverse reactions that are associated with the Licensed Product in the dosage
range to be prescribed; (c) support regulatory approval of such Licensed Product; and (d) be generally consistent with 21 CFR §
312.21(c). Said trial may be conducted in any country.

 

    	 	10	 

     

    

 

“Prosecution Counsel” means the
law firm or attorney who is handling the prosecution of the Patent Rights. Prosecution Counsel as of the Effective Date is identified
in Section 1 of the Patent License Agreement.

 

“Quarterly Payment Deadline” means
the day that is 30 days after the last day of any particular Contract Quarter.

 

“Regulatory Approval” means the
approval by the Regulatory Authority needed for a particular national jurisdiction to market, sell and use a Licensed Product in
that national jurisdiction.

 

“Regulatory Authority” means the
governmental authority responsible for granting any necessary licenses or approvals for the marketing, sale and use of a Licensed
Product or Licensed Service in a particular national jurisdiction, including without limitation, the FDA, European Medicines Agency
or Koseisho (i.e. the Japanese Ministry of Health and Welfare).

 

“Sell, Sale or Sold” means any
transfer or other disposition of Licensed Products or Licensed Services for which consideration is received by Licensee, its Affiliates
or Sublicensees. A Sale of Licensed Products or Licensed Services will be deemed completed at the time Licensee or its Affiliate
or its Sublicensee receives such consideration.

 

“Sublicense Agreement” means any
agreement or arrangement pursuant to which Licensee (or an Affiliate or Sublicensee) grants to any third party any license rights
of Licensee under the Agreement.

 

“Sublicense Fee” means the fee
specified in Section 3.1(d) of the Patent License Agreement.

 

“Sublicensee” means any entity
to whom an express sublicense has been granted under the Patent Rights. For clarity, a third party wholesaler or distributor who
has no significant responsibility for marketing and promotion of the Licensed Product or Licensed Services within its distribution
territory or field (i.e., the third party simply functions as a reseller), and who does not pay any consideration to Licensee or
an Affiliate for such wholesale or distributor rights, shall not be deemed a Sublicensee; and the resale by such a wholesaler or
distributor shall not be treated as royalty bearing Net Sales by a Sublicensee provided that a royalty is being paid by Licensee
for the initial transfer to the wholesaler or distributor pursuant to Section 3.2. This definition does not limit Licensee’s
rights to grant or authorize sublicenses under the Agreement.

 

“Territory” means the territory
so indicated as the Territory in Section 1 of the Patent License Agreement.

 

“Valid Claim” means a claim of
(i) an issued and unexpired patent included within the Patent Rights unless the claim has been held unenforceable or invalid by
the final, un-reversed, and un¬appealable decision of a court or other government body of competent jurisdiction, has been
irretrievably abandoned or disclaimed, or has otherwise been finally admitted or determined to be invalid, un-patentable or unenforceable,
whether through reissue, reexamination, disclaimer or otherwise, or (ii) a pending patent application within the Patent Rights
to the extent the claim continues to be prosecuted in good faith.

 

    	 	11	 

     

    

 

		2.	License Grant and Commercialization

 

		2.1	Grant

 

		(a)	For the Patent Rights listed in Exhibit B, Licensor grants to Licensee a royalty-bearing exclusive license under such Patent
Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed
Products in the Exclusive Field in the Territory and to perform Licensed Services in the Exclusive Field in the Territory.

 

For the Patent Rights listed in Exhibit C, Licensor
grants to Licensee:

 

		1.	a royalty-bearing exclusive license to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell,
lease, loan and/or import Licensed Products in the Limited Exclusive Field in the Territory and to perform Licensed Services in
the Limited Exclusive Field in the Territory, and

 

		2.	a royalty-bearing non-exclusive license to manufacture, have manufactured, distribute, have distributed, use, offer for Sale,
Sell, lease, loan and/or import Licensed Products in the field of vaccines the Territory and to perform Licensed Services in the
field of vaccines the Territory. Both parties agree that Licensor can further license the Patent Rights listed in Exhibit C in
the field of vaccines.

 

		(b)	This grant is subject to (i) the payment by Licensee to Licensor of all consideration required under the Agreement, (ii) any
rights of, or obligations to, the Government as set forth in Section 11.2 (Government Rights), and (iii) rights retained by Licensor
to:

 

		1.	Publish the scientific findings from research related to the Patent Rights; and

 

		2.	Manufacture, have manufactured, and use the Patent Rights for teaching, research, patient care, education, and other educationally-related
purposes; and

 

		3.	Grant rights to, and transfer material embodiments of, the Patent Rights to other academic institutions or non-profit research
institutions for the purposes identified in clauses (1) and (2) above.

 

    	 	12	 

     

    

 

		(c)	Licensor reserves all rights not expressly granted in the Agreement and disclaims the grant of any implied rights to Licensee.

 

		2.2	Affiliates

 

Licensee may extend the license granted herein to any
Affiliate provided that the Affiliate agrees in writing to be bound by the Agreement to the same extent as Licensee. Licensee agrees
to deliver such written agreement to Licensor within 30 calendar days following execution.

 

		2.3	Sublicensing

 

Licensee has the right to grant Sublicense Agreements
under the Patent Rights consistent with the terms of the Agreement, subject to the following:

 

		(a)	A Sublicense Agreement shall not exceed the scope and rights granted to Licensee hereunder. Sublicensee must agree in writing
to be bound by the applicable terms and conditions of the Agreement and shall indicate that Licensor is a third party beneficiary
and entitled to enforce the terms and conditions of the Sublicense Agreement applicable to the Agreement. In the event of termination
of the Agreement, continued sublicense rights shall be governed by Section 7.5(a) (Effect of Termination). Licensee may grant a
Sublicensee the right to grant further sub-Sublicense Agreements, in which case such sub-Sublicense Agreements shall be treated
as “Sublicense Agreements” and such sub-Sublicensees shall be treated as “Sublicensees” for purposes of
the Agreement.

 

		(b)	Licensee shall deliver to Licensor a true, complete, and correct copy of each Sublicense Agreement granted by Licensee, Affiliate
or Sublicensee, and any modification or termination thereof, within 30 days following the applicable execution, modification, or
termination of such Sublicense Agreement. If the Sublicense Agreement is not in English, Licensee shall provide Licensor an accurate
English translation in addition to a copy of the original agreement.

 

		(c)	Notwithstanding any such Sublicense Agreement, Licensee will remain primarily liable to Licensor for all of the Licensee’s
duties and obligations contained in the Agreement, including without limitation the payment of running royalties due under Section
3.2 whether or not paid to Licensee by a Sublicensee. Any act or omission of a Sublicensee that would be a breach of the Agreement
if performed by Licensee will be deemed to be a breach by Licensee unless Licensee complies with the remaining provisions of this
paragraph. Each Sublicense Agreement will contain a right of termination by Licensee in the event that the Sublicensee breaches
the payment or reporting obligations affecting Licensor or any other terms and conditions of the Sublicense Agreement that would
constitute a breach of the Agreement if such acts were performed by Licensee. In the event of a Sublicensee breach, and if after
a reasonable opportunity to cure as provided in any such Sublicense Agreement (not to exceed 30 days for a payment breach and 60
days for a non-payment breach), such Sublicensee fails to cure such Sublicensee breach, then the Licensee will terminate the Sublicense
Agreement within 30 days thereafter, with copy of such written notice of termination to Licensor, unless agreed to in writing otherwise
by Licensor.

 

    	 	13	 

     

    

 

		(d)	If Licensor (as represented by the actual knowledge of the responsible licensing professional in Licensor’s Office of
Technology Commercialization responsible for administration of licensor case nos.: 5612 DOW and 5254 JOH) or a third party discovers
and notifies Licensor that the Patent Rights are useful for an application covered by the Exclusive Field or Limited Exclusive
Field, as appropriate, of use but for which Licensed Products or Licensed Services have not been developed or are not currently
under development by Licensee (“New Use”), then Licensor, may give written notice to Licensee of such New Use and within
ninety (90) days following Licensee’s receipt of Licensor’s notification, Licensee shall give written notice stating
whether Licensee elects to develop Licensed Products or Licensed Services for the New Use.

 

If Licensee elects to develop and commercialize Licensed
Products or Licensed Services for the New Use, Licensee shall submit a commercialization plan along with its election and thereafter
include in future progress reports descriptions of Licensee’s commercialization efforts in developing Licensed Products or
Licensed Services for the New Use pursuant to Section 4 herein.

 

If Licensee elects not to develop and commercialize
Licensed Products or Licensed Services for the New Use, Licensor may refer third parties to Licensee who are willing to develop
Licensed Products or Licensed Services for the New Use. If such third parties request a sublicense under this agreement, then the
Licensee agrees to negotiate in good faith a Sublicense Agreement with any such third party consistent with the terms of Section
2.3.

 

If Licensee is unable or unwilling to enter into a
Sublicense Agreement with any such third party on reasonable terms within sixty (60) days of the referral by Licensor, then Licensor
shall have the right to grant to the third party license rights under the Patent Rights as Licensor deems necessary, in Licensor’s
sole discretion, to serve the New Use, notwithstanding the exclusive license grant of section 2.1.

 

    	 	14	 

     

    

 

		2.4	Diligent Commercialization

 

Licensee by itself or through its Affiliates and Sublicensees
will use diligent efforts to make Licensed Products or Licensed Services commercially available in the Field in the Territory.
Without limiting the foregoing, Licensee will (a) maintain a reasonably funded, ongoing and active research, development, manufacturing,
regulatory, marketing or sales program required to make License Products or Licensed Services commercially available, and (b) fulfill
the milestone events specified in Section 2.4 of the Patent License Agreement by the deadlines indicated therein and (c) use diligent
and commercially reasonable efforts to perform and complete the plans described in the annual report submitted pursuant to Section
4.2 (Annual Written Progress Report). If the obligations under this Section 2.4 are not fulfilled, Licensor may treat such failure
as a breach in accordance with Section 7.3(b).

 

		3.	Compensation

 

In consideration of rights granted to Licensee, Licensee
will pay Licensor the following fees and royalties. All fees and royalties are not refundable and are not creditable against other
fees and royalties except as explicitly set forth herein. Each payment will reference the Patent License Agreement number and will
be sent to Licensor’s payment and accounting contact in Section 18 (Notices) of the Patent License Agreement.

 

		3.1	Non-Royalty Payments due from Licensee

 

		(a)	Patent Expenses. Licensee will reimburse Licensor for the past patent expenses stated in Section 3.1(a) of the Patent
License Agreement by the first anniversary of the Effective Date, subject to Section 20.1 of the Patent License Agreement. The
total amount of past patent expenses due at the first anniversary of the Effective Date shall be paid in five equal amounts due
within 15 days of the first, second, third, fourth, and fifth anniversary of the Effective Date. The stated amount is the current
estimate for past patent expenses based on invoices received by the Licensor through the stated date. Licensee’s obligations
to pay all past and future patent expenses pursuant to Section 6 (Patent Expenses and Prosecution) will not be limited by such
amount. With respect to the past patent expenses of the Patent Rights listed in Exhibit C, payments received by Licensor for such
past patent expenses from a third party licensee may reduce the amount payable by Licensee.

 

		(b)	Milestone Fees. Licensee will pay Milestone Fees indicated in Section 3.1(b) and 20.2 of the Patent License Agreement
by the Quarterly Payment Deadline for the Contract Quarter in which the milestone events set forth in Section 3.1(b) and 20.2 of
the Patent License Agreement are achieved.

 

		(c)	Scheduled License Fees. Licensee will pay license fees in the amounts set forth in Sections 3.1(c) of the Patent License
Agreement in accordance with the stated schedule.

 

    	 	15	 

     

    

 

		(d)	Sublicense Fees. Licensee will pay Sublicense Fees indicated in Section 3.1(d) of the Patent License Agreement on or
before the Quarterly Payment Deadline for the Contract Quarter.

 

		(e)	Assignment Fee. Licensee will pay the assignment fee set forth in Section 3.1(e) of the Patent License Agreement within
15 days of the assignment of the Agreement.

 

		(f)	FDA Priority Review Voucher: If Licensee receives a voucher under the FDA’s priority review voucher program, Licensee
may sell or otherwise commercialize such voucher, if Licensee pays Licensor twenty-five percent (25%) of all proceeds related to
the sale of such voucher within thirty (30) days after receipt of such proceeds.

 

		3.2	Royalties

 

Licensee will pay a running royalty at the rate set
forth in Section 3.2 of the Patent License Agreement on Net Sales in each Contract Quarter, payable on or before the Quarterly
Payment Deadline for such Contract Quarter, subject to the following:

 

		(a)	No more than one royalty shall be paid to Licensor hereunder with respect to the Sale of any one unit of Licensed Product or
Licensed Service, whether or not more than one patent or Valid Claim is applicable to the Licensed Product or Licensed Service,
or the development, manufacture, or performance thereof.

 

		(b)	No royalty shall be payable under this Section 3.2 with respect to (i) Sales to an Affiliate or Sublicensee of a particular
unit of Licensed Product that is used by such Affiliate or Sublicensee to perform a Licensed Service if Licensor is paid a royalty
on the Sale of such Licensed Service, (ii) the Sale of Licensed Products between or among Licensee, its Affiliates, and Sublicensees
for re-sale purposes, provided Licensor is paid a royalty with respect to the re-sale, or (iii) payments that constitute Non-Royalty
Sublicensing Consideration.

 

		3.3	Non-cash Consideration

 

If Licensee receives or anticipates receipt of non-cash
consideration from Sales or Sublicenses, the manner in which Licensor will receive its compensation under the Agreement with respect
to such non-cash consideration will be negotiated in good faith and timely agreed to by the Parties.

 

		4.	Reports and Plans

 

The reports specified in thrs Section 4 will be sent
to Licensors payment and reporting contact identified in Section 18 (Notices) of the Patent License Agreement. If Licensor requests
to have information submitted in a particular format, Licensee will use reasonable efforts to comply with such request.

 

    	 	16	 

     

    

 

		4.1	Quarterly Payment and Milestone Reports

 

On or before each Quarterly Payment Deadline, Licensee
will deliver to Licensor a true and accurate report, certified by an officer of Licensee, giving such particulars of the business
conducted by Licensee, its Affiliates and its Sublicensees (including copies of reports provided by Sublicensees and Affiliates
to Licensee) during the preceding Contract Quarter under the Agreement as necessary for Licensor to account for Licensee’s
payments hereunder, even if no payments are due. The reports shall continue to be delivered after the termination or expiration
of the Agreement until such time as all Licensed Products permitted to be Sold after termination or expiration have been Sold or
destroyed. Licensee shall provide information in sufficient detail to enable the royalties payable hereunder to be determined and
to calculate all of the amounts payable under the Agreement. The report shall include:

 

		(a)	The name of the Licensee, the Patent License Agreement number, and the period covered by the report;

 

		(b)	The name of any Affiliates and Sublicensees whose activities are also covered by the report;

 

		(c)	Identification of each Licensed Product and Licensed Service for which any royalty payments have become payable;

 

		(d)	Net Product Sales and Net Service Sales segregated on a product-by-product basis, and a country-by-country basis, or an affirmative
statement that no Sales were made. The report shall also itemize the permitted deductions from the Gross Consideration used to
arrive at the resulting Net Product Sales and Net Service Sales, on a product-by-product and country-by-country basis;

 

		(e)	The applicable royalty rate;

 

		(f)	An affirmative statement of whether any milestones with deadlines in that Contract Quarter under Section 2.4 and any milestones
under Section 3.1(b) were met or not, and the resulting Milestone Fee payable;

 

		(g)	Non-Royalty Sublicensing Consideration received by Licensee segregated on a Sublicense-by-Sublicense basis, or an affirmative
statement that none was received;

 

		(h)	If any consideration was received in currencies other than U.S. dollars, the report shall describe the currency exchange calculations;
and

 

    	 	17	 

     

    

 

		(i)	Any changes in accounting methodologies used to account for and calculate the items included in the report since the previous
report.

 

		4.2	Annual Written Progress Report and Commercialization Plan

 

Within 45 days following the end of each Contract Year,
Licensee will deliver to Licensor a true and accurate written progress report and commercialization plan, certified by an officer
of Licensee, that summarizes (i) Licensee’s efforts and accomplishments during the Contract Year to diligently commercialize
Licensed Products and Licensed Services, and (ii) Licensee’s development and commercialization plans with respect to Licensed
Products and Licensed Services for the next Contract Year. The report shall also cover such activities by Affiliates and Sublicensees.
The report shall contain the following information to the extent relevant to the activities under the Agreement:

 

		(a)	The name of the Licensee, the Patent License Agreement number, the names of any Affiliates and Sublicensees, and the products
and services being developed and/or commercialized;

 

		(b)	The progress toward completing and the plans for completing the applicable milestone events pursuant to Sections 2.4 and 3.1(b);

 

		(c)	The research and development activities, including status and plans for obtaining any necessary governmental approvals, performed
during the past year, and the plans for research and development activities for the next year; and

 

		(d)	The marketing activities for the past year and planned for the next year, and Licensee’s internal estimate for Sales
for the next year.

 

		4.3	Government and Economic Development Reporting

 

If Licensor requests, Licensee will provide information
for Licensor’s Government and economic development reporting purposes, including the following:

 

		(a)	Number and geographic location of new full-time employees created during the past Contract Year; total number and geographic
location of full-time employees of Licensee at the end of such Contract Year;

 

		(b)	Dollar amount of new equity financing received by Licensee during the past Contract Year, and current capitalization, including
number and class of outstanding securities;

 

		(c)	Location and square footage of facilities; and

 

		(d)	Other information required under Federal and state law.

 

    	 	18	 

     

    

 

This information shall be treated as Licensee’s
Confidential Information; provided that Licensor is entitled to combine such information with similar information from other Licensor
licensees and publicly report such combined aggregate information, without identifying Licensee’s separate specific applicable
numbers. If and when Licensee has more than 200 full-time employees, then no further economic development reports will be required
from Licensee.

 

		5.	Payment, Records, and Audits

 

		5.1	Payments

 

All amounts referred to in the Patent License Agreement
are expressed in U.S. dollars without deductions for taxes, assessments, fees, or charges of any kind. Each payment will reference
the agreement number set forth at the beginning of the Patent License Agreement. All payments to Licensor will be made in U.S.
dollars by check or wire transfer (Licensee to pay all wire transfer fees) payable to the payee identified in Section 18 of the
Patent License Agreement and sent to the payment and reporting contact in Section 18 (Notices) of the Patent License Agreement.

 

		5.2	Sales Outside the U.S.

 

If any currency conversion shall be required in connection
with the calculation of payments hereunder, such conversion shall be made using the rate used by Licensee for its financial reporting
purposes in accordance with Generally Accepted Accounting Principles (or foreign equivalent) or, in the absence of such rate, using
the average of the buying and selling exchange rate for conversion between the foreign currency and U.S. Dollars, for current transactions
as reported in The Wall Street Journal on the last business days of the Contract Quarter to which such payment pertains. Licensee
may not make any tax withholdings from payments to Licensor, but Licensor agrees to supply to Licensee, upon written request, appropriate
evidence from appropriate U.S. governmental agencies showing that Licensor is a resident of the United States of America for purposes
of the U.S. income tax laws and is tax-exempt under such income tax laws.

 

		5.3	Late Payments

 

Amounts that are not paid when due will accrue a late
charge from the due date until paid, at a rate equal to 1.0% per month (or the maximum allowed by law, if less).

 

		5.4	Records

 

For a period of six years after the Contract Quarter
to which the records pertain, Licensee agrees that it and its Affiliates and Sublicensees will each keep complete and accurate
records of their Sales, Net Product Sales, Net Service Sales, Milestone Fees, and Non-Royalty Sublicensing Consideration in sufficient
detail to enable such payments to be determined and audited.

 

    	 	19	 

     

    

 

		5.5	Auditing

 

Licensee and its Affiliates will permit Licensor or
its representatives, at Licensor’s expense, to periodically examine books, ledgers, and records during regular business hours,
at Licensee’s or its Affiliate’s place of business, on at least 30 days advance notice, to the extent necessary to
verify any payment or report required under the Agreement. For each Sublicensee, Licensee shall obtain such audit rights for Licensor
or itself. If Licensee obtains such audit rights for itself, it will promptly conduct an audit of the Sublicensee’s records
upon Licensor’s request, and Licensee will furnish to Licensor a copy of the findings from such audit. No more than one audit
of Licensee, each Affiliate, and each Sublicensee shall be conducted under this Section 5.5 in any calendar year. If any amounts
due Licensor have been underpaid, then Licensee shall immediately pay Licensor the amount of such underpayment plus accrued interest
due in accordance with Section 5.3. If the amount of underpayment is equal to or greater than 5% of the total amount due for the
records so examined, Licensee will pay the cost of such audit. Such audits may, at Licensor’s sole discretion, consist of
a self-audit conducted by Licensee at Licensee’s expense and certified in writing by an authorized officer of Licensee. All
information examined pursuant to this Section 5.5 shall be deemed to be the Confidential Information of the Licensee. Further,
whenever Licensee and/or its Affiliates and Sublicensees has its books and records audited by an independent certified public accountant,
Licensee and/or its Affiliates and Sublicensees will, within 30 days of the conclusion of such audit, provide Licensor with a written
statement of said auditor, setting forth the calculation of amounts due to Licensor over the time period audited, as determined
from the books and records of the Licensee, Affiliate or Sublicensee; but said auditor does not need to give any audit opinion
with said statement.

 

		6.	Patent Expenses and Prosecution

 

		6.1	Patent Expenses

 

Licensee shall pay for all past (subject to Section
20.1 of the Patent License Agreement) documented, out-of-pocket expenses incurred by Licensor for filing, prosecuting, enforcing,
defending and maintaining Patent Rights and related patent searches through the Effective Date of the Agreement, including those
identified in Section 3.1(a) of the Patent License Agreement, and all such future expenses incurred by Licensor, for so long as,
and in such countries as the Agreement remains in effect. Licensee will pay all patent expenses (except for the payment called
for under Section 3.1(a)), including past expenses (subject to Section 20.1 of the Patent License Agreement) that have not been
invoiced as of the date indicated in Section 3.1(a) of the Patent License Agreement and future expenses, within 30 days after Licensee’s
receipt of an invoice. At the election of Licensor, Licensee will either pay Prosecution Counsel directly for patent expenses or
will reimburse Licensor for such patent expenses. Patent expense payment delinquencies (whether owed directly to Prosecution Counsel
or to Licensor) will be considered a payment default under Section 7.3(a).

 

    	 	20	 

     

    

 

		6.2	Direction of Prosecution

 

Licensor will confer with Licensee to develop a strategy
for the prosecution and maintenance of Patent Rights. Licensor will request that copies of all documents prepared by the Prosecution
Counsel for submission to governmental patent offices be provided to Licensee for review and comment prior to filing, to the extent
practicable under the circumstances. At its discretion, Licensor may allow Licensee to instruct Prosecution Counsel directly, provided,
that (a) Licensor will maintain final authority in all decisions regarding the prosecution and maintenance of the Patent Rights,
(b) Licensor may revoke this authorization to instruct Prosecution Counsel directly at any time, and (c) the Prosecution Counsel
remains counsel to the Licensor with an appropriate contract (and shall not jointly represent Licensee unless requested by Licensee
and approved by Licensor, and an appropriate engagement letter and conflict waiver are in effect). If Licensee wishes to instruct
Prosecution Counsel directly or change Prosecution Counsel, Licensee may request to do so by following the Licensor’s procedures
for such. Licensor reserves in its sole discretion the ability to change Prosecution Counsel and to approve or disapprove any requested
changes by Licensee. The Parties agree that they share a common legal interest to get valid enforceable patents and that Licensee
will maintain as privileged all information received pursuant to this Section.

 

		6.3	Ownership

 

All patent applications and patents will be in the name
of Licensor (and any co-owner identified in Section 1 of the Patent License Agreement) and owned by Licensor (and such co-owner,
if any). No payments due under the Agreement will be reduced as the result of co-ownership interests in the Patent Rights by Licensee
or any other party.

 

		6.4	Foreign Filings

 

In addition to the U.S., the Patent Rights shall, subject
to applicable bar dates, be pursued in such foreign countries as Licensee so designates in writing to Licensor in sufficient time
to reasonably enable the preparation of such additional filings, and in those foreign countries in which Licensor has filed applications
prior to the Effective Date. If Licensee does not choose to pursue patent rights in a particular foreign country and Licensor chooses
to do so, Licensor shall so notify Licensee and thereafter said patent application or patent shall no longer be included in the
Patent Rights and Licensee shall have no further rights thereto. Licensor shall have the right to make alternative arrangements
with Licensee for upfront payment of foreign patent expenses.

 

    	 	21	 

     

    

 

		6.5	Withdrawal from Paying Patent Costs

 

If at any time Licensee wishes to cease paying for any
costs for any particular Patent Rights or for patent prosecution in a particular jurisdiction, Licensee must give Licensor at least
90 days prior written notice and Licensee will continue to be obligated to pay for the patent costs which reasonably accrue during
said notice period. Thereafter, said patent application or patent shall no longer be included in the Patent Rights and Licensee
shall have no further rights thereto.

 

		6.6	U.S. Patent and Trademark Office Entity Size Status

 

Licensee represents that as of the Effective Date the
entity size status of Licensee in accordance with the regulations of the U.S. Patent and Trademark Office is as set forth in Section
1 of the Patent License Agreement. Licensee will inform Licensor in writing on a timely basis of any change in its U.S. Patent
and Trademark Office entity size status.

 

		6.7	Extension of Patent Term

 

If a Licensed Product is eligible for extending the
term of any patent in the Patent Rights under the Drug Price Competition and Patent Term Restoration Act of 1984 and/or any European,
Japanese, or other foreign counterparts of this law, then Licensee shall take all necessary steps with the appropriate regulatory
authorities to apply in a timely manner for such an extension of the term for such patent. For example, such application must be
made to the USPTO within sixty (60) days after the US FDA approves a commercial marketing application for said Licensed Product.
Licensee shall prepare and file all documents needed for the application; and Licensee shall take all reasonable actions as may
be appropriate to further obtain patent term extension. Licensor shall cooperate and sign such documents as may be reasonably requested
by Licensee for the application.

 

Licensee shall keep Licensor informed as to Licensee’s
efforts to prepare and file said application, including giving a written report within thirty (30) days after Licensee obtains
the applicable marketing approval from the FDA (or foreign counterpart). If Licensee fails to make this required application, then
Licensor shall have the option but not the obligation to do so; and if Licensor does elect to file the application, then Licensee
shall cooperate and sign such documents as may be needed; and Licensee shall reimburse Licensor’s costs incurred for said
application.

 

		7.	Term and Termination

 

		7.1	Term

 

Unless earlier terminated as provided herein, the term
of the Agreement will commence on the Effective Date and continue until the last date of expiration or termination of the Patent
Rights.

 

    	 	22	 

     

    

 

		7.2	Termination by Licensee

 

Licensee, at its option, may terminate the Agreement
by providing Licensor written notice of intent to terminate, which such termination effective will be 90 days following receipt
of such notice by Licensor.

 

		7.3	Termination by Licensor

 

Licensor, at its option, may immediately terminate the
Agreement, or any part of Patent Rights, or any part of Field, or any part of Territory, or the exclusive nature of the license
grant, upon delivery of written notice to Licensee of Licensor’s decision to terminate, if any of the following occur:

 

		(a)	Licensee becomes in arrears in any payments due under the Agreement, and Licensee fails to make the required payment within
30 days after delivery of written notice from Licensor; or

 

		(b)	Licensee is in breach of any non-payment provision of the Agreement, and does not cure such breach within 60 days after delivery
of written notice from Licensor; or

 

		(c)	Licensor delivers notice to Licensee of three or more actual breaches of the Agreement in any 12-month period, even in the
event that Licensee cures such breaches in the allowed period; or

 

		(d)	Licensee or its Affiliate or Sublicensee initiates any proceeding or action to challenge the validity, enforceability, or scope
of one or more of the Patent Rights, or assist a third party in pursuing such ,) proceeding or action.

 

		7.4	Other Conditions of Termination

 

The Agreement will terminate:

 

		(a)	Immediately without the necessity of any action being taken by Licensor or Licensee, (i) if Licensee becomes bankrupt or insolvent,
or (ii) Licensee’s Board of Directors elects to liquidate its assets or dissolve its business, or (iii) Licensee ceases its
business operations, or (iv) Licensee makes an assignment for the benefit of creditors or (v) if the business or assets of Licensee
are otherwise placed in the hands of a receiver, assignee or trustee, whether by voluntary act of Licensee or otherwise; or

 

		(b)	At any time by mutual written agreement between Licensee and Licensor.

 

		7.5	Effect of Termination

 

If the Agreement is terminated for any reason:

 

    	 	23	 

     

    

 

		(a)	All rights and licenses of Sublicensees shall terminate upon termination of the Agreement; provided however, if the Sublicense
Agreement is for all of the Field for all of the Territory, and the Sublicensee is in good standing and agrees in writing to assume
all of the obligations of Licensee and provides Licensor with written notice thereof within 30 days after termination of the Agreement,
then such Sublicense Agreement shall survive; and

 

		(b)	Licensee shall cease making, having made, distributing, having distributed, using, selling, offering to sell, leasing, loaning
and importing any Licensed Products and performing Licensed Services by the effective date of termination; and

 

		(c)	Licensee shall tender payment of all accrued royalties and other payments due to Licensor as of the effective date of termination;
and

 

		(d)	Nothing in the Agreement will be construed to release either Party from any obligation that matured prior to the effective
date of termination; and

 

		(e)	The provisions of Sections 8 (Confidentiality), 9 (Infringement and Litigation), 11 (Representations and Disclaimers), 12 (Limit
of Liability), 13 (Indemnification), 14 (Insurance), 17 (Use of Name), 18 (Notices), and 19 (General Provisions) will survive any
termination or expiration of the Agreement. In addition, the provisions of Sections 3 (Compensation), 4.1 (Quarterly Payment and
Milestone Reports), 5 (Payment, Records and Audits), 6.1 (Patent Expenses), and Section 20.2 of the Patent License Agreement shall
survive with respect to all activities and payment obligations accruing prior to the termination or expiration of the Agreement.

 

		8.	Confidentiality

 

		8.1	Definition

 

“Confidential Information” means
all information that is of a confidential and proprietary nature to Licensor or Licensee and provided by one Party to the other
Party under the Agreement.

 

		8.2	Protection and Marking

 

Licensor and Licensee each agree that all Confidential
Information disclosed in tangible form, and marked “confidential” and forwarded to one by the other, or if disclosed
orally, is designated as confidential at the time of disclosure: (i) is to be held in strict confidence by the receiving Party,
(ii) is to be used by and under authority of the receiving Party only as authorized in the Agreement, and (iii) shall not be disclosed
by the receiving Party, its agents or employees without the prior written consent of the disclosing Party or as authorized in the
Agreement. Licensee has the right to use and disclose Confidential Information of Licensor reasonably in connection with the exercise
of its rights under the Agreement, including without limitation disclosing to Affiliates, Sublicensees, potential investors, acquirers,
and others on a need to know basis, if such Confidential Information is provided under conditions which reasonably protect the
confidentiality thereof. Each Party’s obligation of confidence hereunder includes, without limitation, using at least the
same degree of care with the disclosing Party’s Confidential Information as it uses to protect its own Confidential Information,
but always at least a reasonable degree of care.

 

    	 	24	 

     

    

 

		8.3	Confidentiality of Terms of Agreement

 

Each Party agrees not to disclose to any third party
the terms of the Agreement without the prior written consent of the other Party hereto, except each Party may disclose the terms
of the Agreement: (a) to advisors, actual or potential Sublicensees, acquirers or investors, and others on a need to know basis,
in each case, under appropriate confidentiality obligations substantially similar to those of this Section 8; and (b) to the extent
necessary to comply with applicable laws and court orders (including, without limitation, The Texas Public Information Act, as
may be amended from time to time, other open records laws, decisions and rulings, and securities laws, regulations and guidance).
If the Agreement is not for all fields of use, then Licensor may disclose the Field to other potential third party licensees. Notwithstanding
the foregoing, the existence of the Agreement shall not be considered Confidential Information.

 

		8.4	Disclosure Required by Court Order or Law

 

If the receiving Party is required to disclose Confidential
Information of another Party hereto, or any terms of the Agreement, pursuant to the order or requirement of a court, administrative
agency, or other governmental body or applicable law, the receiving Party may disclose such Confidential Information or terms to
the extent required, provided that the receiving Party shall use reasonable efforts to provide the disclosing Party with reasonable
advance notice thereof to enable the disclosing Party to seek a protective order and otherwise seek to prevent such disclosure.
To the extent that Confidential Information so disclosed does not become part of the public domain by virtue of such disclosure,
it shall remain Confidential Information protected pursuant to Section 8.

 

		8.5	Copies

 

Each Party agrees not to copy or record any of the Confidential
Information of the other Party, except as reasonably necessary to exercise its rights or perform its obligations under the Agreement,
and for archival and legal purposes.

 

		8.6	Continuing Obligations

 

Subject to the exclusions listed in Section 8.7, the
Parties’ confidentiality obligations under the Agreement will survive termination of the Agreement and will continue for
a period of five years thereafter.

 

    	 	25	 

     

    

 

		8.7	Exclusions

 

Information shall not be considered Confidential Information
of a disclosing Party under the Agreement to the extent that the receiving Party can establish by competent written proof that
such information:

 

		(a)	Was in the public domain at the time of disclosure; or

 

		(b)	Later became part of the public domain through no act or omission of the recipient Party, its employees, agents, successors
or assigns in breach of the Agreement; or

 

		(c)	Was lawfully disclosed to the recipient Party by a third party having the right to disclose it not under an obligation of confidentiality;
or

 

		(d)	Was already known by the recipient Party at the time of disclosure; or

 

		(e)	Was independently developed by the recipient Party without use of the disclosing Party’s Confidential Information.

 

		8.8	Copyright Notice

 

The placement of a copyright notice on any Confidential
Information will not be construed to mean that such information has been published and will not release the other Party from its
obligation of confidentiality hereunder.

 

		9.	Infringement and Litigation

 

		9.1	Notification

 

If either Licensee or Licensor’s designated office
for technology commercialization becomes aware of any infringement or potential infringement of Patent Rights in the Field in the
Territory, such Party shall give prompt written notice to the other Party of such infringement.

 

		9.2	Enforcement Against Infringer.

 

Licensor shall have the right, but no obligation, to
enforce the Patent Rights against any infringement by a third party. Licensor shall confer with Licensee and give due consideration
to Licensee’s input concerning any such enforcement action. If an action is to be commenced, Licensor and Licensee will endeavor
to reach mutual agreement as to how best (i) to prosecute, manage, and fund such action, and (ii) to allocate equitably any net
recovery resulting from such action. Licensee is not entitled to commence any enforcement action against an infringer unless Licensor
expressly approved in writing for Licensee to do so, which approval may not be unreasonably withheld. If an enforcement action
is to be commenced, both Parties agree to cooperate fully with each other and to permit reasonable access to all relevant personnel,
records, papers, information, samples, specimens, etc., relevant to the action.

 

    	 	26	 

     

    

 

		9.3	Cooperation between Licensor and Licensee

 

In any infringement suit or dispute, the Parties agree
to cooperate fully with each other. At the request of the Party bringing suit, the other Party will permit reasonable access after
reasonable advance notice to all relevant personnel, records, papers, information, samples, specimens, etc., during regular business
hours.

 

If it is necessary to name Licensor as a party in such
action, then Licensee must first obtain Licensor’s prior written permission, which permission shall not be unreasonably withheld,
provided that Licensor shall have reasonable prior input on choice of counsel on any matter where such counsel represents Licensor,
and Licensee and such counsel agree to follow all required procedures of the Texas Attorney General regarding retention of outside
counsel for state entities.

 

		10.	Export Compliance

 

Licensee understands that the Arms Export Control Act
(AECA), including its implementing International Traffic In Arms Regulations (ITAR), and the Export Administration Act (EAA), including
its Export Administration Regulations (EAR), are some (but not all) of the laws and regulations that comprise the U.S. export laws
and regulations. Licensee further understands that the U.S. export laws and regulations include (but are not limited to): (a) ITAR
and EAR product/service/data-specific requirements; (b) ITAR and EAR ultimate destination-specific requirements; (c) ITAR and EAR
end user-specific requirements; (d) Foreign Corrupt Practices Act; and (e) anti-boycott laws and regulations. Licensee will comply
with all then-current applicable export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations)
pertaining to the Licensed Products and Licensed Services (including any associated products, items, articles, computer software,
media, services, technical data, and other information). Licensee certifies that it will not, directly or indirectly, export (including
any deemed export), nor re-export (including any deemed re-export) the Licensed Products and Licensed Services (including any associated
products, items, articles, computer software, media, services, technical data, and other information) in violation of applicable
U.S. laws and regulations. Licensee will include a provision in its agreements, substantially similar to this Section 10, with
its Sublicensees, third party wholesalers and distributors, and physicians, hospitals or other healthcare providers who purchase
a Licensed Product, requiring that these parties comply with all then-current applicable U.S. export laws and regulations and other
applicable U.S. laws and regulations.

 

    	 	27	 

     

    

 

		11.	Representations and Disclaimers

 

		11.1	Licensor Representations

 

Except for the rights, if any, of the Government as
set forth in Section 11.2, Licensor represents and warrants to Licensee that to the knowledge of Licensor’s designated office
for technology commercialization (i) Licensor is the owner or agent of the entire right, title, and interest in and to Patent Rights
(other than the right, title and interest of any joint owner identified in Section 1 of the Patent License Agreement), (ii) Licensor
has the right to grant licenses hereunder, and (iii) Licensor has not knowingly granted and will not knowingly grant licenses or
other rights under the Patent Rights that are in conflict with the terms and conditions in the Agreement.

 

		11.2	Government Rights

 

Licensee understands that Patent Rights may have been
developed under a funding agreement with Government and, if so, that Government may have certain rights relative thereto. The Agreement
is made subject to the Government’s rights under any such agreement and under any applicable Government law or regulation.
To the extent that there is a conflict between any such agreement, such applicable law or regulation and the Agreement, the terms
of such Government agreement, and applicable law or regulation, shall prevail. Licensee agrees that, to the extent required by
U.S. laws and regulations, Licensed Products used or Sold in the U.S. will be manufactured substantially in the U.S., unless a
written waiver is obtained in advance from the U.S. Government.

 

		11.3	Licensor Disclaimers

 

EXCEPT AS SPECIFICALLY SET FORTH IN SECTION 11.1, LICENSEE
UNDERSTANDS AND AGREES THAT LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT
LIMITATION, AS TO THE LICENSED PRODUCTS OR LICENSED SERVICES, OR AS TO THE OPERABILITY OR FITNESS FOR ANY USE OR PARTICULAR PURPOSE,
MERCHANTABILITY, SAFETY, EFFICACY, APPROVABILITY BY REGULATORY AUTHORITIES, TIME AND COST OF DEVELOPMENT, PATENTABILITY, AND/OR
BREADTH OF PATENT RIGHTS. LICENSOR MAKES NO REPRESENTATION AS TO WHETHER ANY PATENT WITHIN PATENT RIGHTS IS VALID, OR AS TO WHETHER
THERE ARE ANY PATENTS NOW HELD, OR WHICH WILL BE HELD, BY OTHERS OR BY LICENSOR THAT MIGHT BE REQUIRED FOR USE OF PATENT RIGHTS
IN FIELD. NOTHING IN THE AGREEMENT WILL BE CONSTRUED AS CONFERRING BY IMPLICATION, ESTOPPEL OR OTHERWISE ANY LICENSE OR RIGHTS
TO ANY PATENTS OR TECHNOLOGY OF LICENSOR OTHER THAN THE PATENT RIGHTS, WHETHER SUCH PATENTS ARE DOMINANT OR SUBORDINATE TO THE
PATENT RIGHTS. LICENSOR HAS NO OBLIGATION TO FURNISH TO LICENSEE ANY KNOW-HOW, TECHNOLOGY OR TECHNOLOGICAL INFORMATION.

 

    	 	28	 

     

    

 

		11.4	Licensee Representation

 

By execution of the Agreement, Licensee represents,
acknowledges, covenants and agrees (a) that Licensee has not been induced in any way by Licensor or its employees to enter into
the Agreement, and (b) that Licensee has been given an opportunity to conduct sufficient due diligence with respect to all items
and issues pertaining to this Section 11 (Representations and Disclaimers) and all other matters pertaining to the Agreement; and
(c) that Licensee has adequate knowledge and expertise, or has utilized knowledgeable and expert consultants, to adequately conduct
the due diligence, and (c) that Licensee accepts all risks inherent herein. Licensee represents that it is a duly organized, validly
existing entity of the form indicated in Section 1 of the Patent License Agreement, and is in good standing under the laws of its
jurisdiction of organization as indicated in Section 1 of the Patent License Agreement, and has all necessary corporate or other
appropriate power and authority to execute, deliver and perform its obligations hereunder.

 

		12.	Limit of Liability

 

IN NO EVENT SHALL LICENSOR, THE UNIVERSITY SYSTEM
IT GOVERNS, ITS MEMBER INSTITUTIONS, INVENTORS, REGENTS, OFFICERS, EMPLOYEES, STUDENTS, AGENTS OR AFFILIATED ENTERPRISES, BE LIABLE
FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY, OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR
LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER ANY
SUCH PARTY KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES. OTHER THAN FOR CLAIMS AGAINST LICENSEE FOR INDEMNIFICATION
(SECTION 13) OR FOR MISUSE OR MISAPPROPRIATION OR INFRINGEMENT OF LICENSOR’S INTELLECTUAL PROPERTY RIGHTS, LICENSEE WILL
NOT BE LIABLE TO LICENSOR FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL OR PUNITNE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR
LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER LICENSEE
KNOWS OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES.

 

    	 	29	 

     

    

 

		13.	Indemnification

 

		13.1	Indemnification Obligation

 

Subject to Section 13.2, Licensee agrees to hold harmless,
defend and indemnify Licensor, the university system it governs, its member institutions, its Regents, officers, employees, students
and agents (“Indemnified Parties”) from and against any liabilities, damages, causes of action, suits, judgments,
liens, penalties, fines, losses, costs and expenses (including, without limitation, reasonable attorneys’ fees and other
expenses of litigation) (collectively “Liabilities”) resulting from claims or demands brought by third parties
against an Indemnified Party on account of any injury or death of persons, damage to property, or any other damage or loss arising
out of or in connection with the Agreement or the exercise or practice by or under authority of Licensee, its Affiliates or their
Sublicensees, or third party wholesalers or distributors, or physicians, hospitals or other healthcare providers who purchase a
Licensed Product, of the rights granted hereunder.

 

		13.2	Conditions of Indemnification

 

Licensee shall have no responsibility or obligation
under Section 13.1 for any Liabilities to the extent caused by the gross negligence or willful misconduct by Licensor. Obligations
to indemnify, and hold harmless under Section 13.1 are subject to: (a) to the extent authorized by the Texas Constitution and the
laws of the State of Texas, and subject to the statutory duties of the Texas Attorney General, the Indemnified Party giving Licensee
control of the defense and settlement of the claim and demand; and (b) to the extent authorized by the Texas Constitution and the
laws of the State of Texas and subject to statutory duties of the Texas Attorney General, the Indemnified Party providing assistance
reasonably requested by Licensee, at Licensee’s expense.

 

		14.	Insurance

 

		14.1	Insurance Requirements

 

Prior to any Licensed Product being used or Sold (including
for the purpose of obtaining regulatory approvals), and prior to any Licensed Service being performed by Licensee, an Affiliate,
or by a Sublicensee, and for a period of five years after the Agreement expires or is terminated, Licensee shall, at its sole cost
and expense, procure and maintain commercial general liability insurance in commercially reasonable and appropriate amounts for
the Licensed Product being used or Sold or the Licensed Service being performed. Licensee shall use commercially reasonable efforts
to have Licensor, the university system it governs, its member institutions, Regents, officers, employees, students and agents
named as additional insureds. Such commercial general liability insurance shall provide, without limitation: (i) product liability
coverage; (ii) broad form contractual liability coverage for Licensee’s indemnification under the Agreement; and (iii) coverage
for litigation costs.

 

		14.2	Evidence of Insurance and Notice of Changes

 

Upon request by Licensor, Licensee shall provide Licensor
with written evidence of such insurance. Additionally, Licensee shall provide Licensor with written notice of at least 60 days
prior to Licensee cancelling, not renewing, or materially changing such insurance.

 

    	 	30	 

     

    

 

		15.	Assignment

 

The Agreement may not be assigned by Licensee without
the prior written consent of Licensor, which consent will not be unreasonably withheld. A merger or other transaction in which
the equity holders of Licensee prior to such event hold less than a majority of the equity of the surviving or acquiring entity
shall be considered an assignment of the Agreement. For any permitted assignment to be effective, (a) Licensee must be in good
standing under this Agreement, (b) the Licensee must pay Licensor the assignment fee pursuant to Section 3.1(e), and (c) the assignee
must assume in writing (a copy of which shall be promptly provided to Licensor) all of Licensee’s interests, rights, duties
and obligations under the Agreement and agree to comply with all terms and conditions of the Agreement as if assignee were an original
Party to the Agreement.

 

		16.	Governmental Markings

 

		16.1	Patent Markings

 

Licensee agrees that all Licensed Products Sold by Licensee,
Affiliates, or Sublicensees will be legibly marked with the number of any applicable patent(s) licensed hereunder as part of the
Patent Rights in accordance with each country’s patent marking laws, including Title 35, U.S. Code, or if such marking is
not practicable, shall so mark the accompanying outer box or product insert for Licensed Products accordingly.

 

		16.2	Governmental Approvals and Marketing of Licensed Products and or Licensed Services

 

Licensee will be responsible for obtaining all necessary
governmental approvals for the development, production, distribution, Sale, and use of any Licensed Product or performance of any
Licensed Service, at Licensee’s expense, including, without limitation, any safety studies. Licensee will have sole responsibility
for any warning labels, packaging and instructions as to the use and the quality control for any Licensed Product or Licensed Service.

 

		16.3	Foreign Registration and Laws

 

Licensee agrees to register the Agreement with any foreign
governmental agency that requires such registration; and Licensee will pay all costs and legal fees in connection with such registration.
Licensee is responsible for compliance with all foreign laws affecting the Agreement or the Sale of Licensed Products and Licensed
Services to the extent there is no conflict with United States law, in which case United States law will control.

 

    	 	31	 

     

    

 

		17.	Use of Name

 

Licensee will not use the name, trademarks or other
marks of Licensor (or the name of the university system it governs, its member institutions, any of its Regents or employees) without
the advance written consent of Licensor. Licensor may use Licensee’s name and logo for annual reports, brochures, website,
and internal reports without prior consent.

 

		18.	Notices

 

Any notice or other communication of the Parties required
or permitted to be given or made under the Agreement will be in writing and will be deemed effective when sent in a manner that
provides confirmation or acknowledgement of delivery and received at the address set forth in Section 18 of the Patent License
Agreement (or as changed by written notice pursuant to this Section 18). Notices required under the Agreement may be delivered
via E-mail provided such notice is confirmed in writing as indicated.

 

Notices shall be provided to each Party as specified
in the “Contact for Notice” address set forth in Section 18 of the Patent License Agreement. Each Party shall update
the other Party in writing with any changes in such contact information.

 

		19.	General Provisions

 

		19.1	Binding Effect

 

The Agreement is binding upon and inures to the benefit
of the Parties hereto, their respective executors, administrators, heirs, permitted assigns, and permitted successors in interest.

 

		19.2	Construction of Agreement

 

Headings are included for convenience only and will
not be used to construe the Agreement. The Parties acknowledge and agree that both Parties substantially participated in negotiating
the provisions of the Agreement; therefore, both Parties agree that any ambiguity in the Agreement shall not be construed more
favorably toward one Party than the other Party, regardless of which Party primarily drafted the Agreement.

 

		19.3	Counterparts and Signatures

 

The Agreement may be executed in multiple counterparts,
each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument. A Party
may evidence its execution and delivery of the Agreement by transmission of a signed copy of the Agreement via facsimile or email.

 

		19.4	Compliance with Laws

 

Licensee will comply with all applicable federal,
state and local laws and regulations, including, without limitation, all export laws and regulations.

 

    	 	32	 

     

    

 

		19.5	Governing Law

 

The Agreement will be construed and enforced in accordance
with laws of the U.S. and the State of Texas, without regard to choice of law and conflicts of law principles.

 

		19.6	Modification

 

Any modification of the Agreement will be effective
only if it is in writing and signed by duly authorized representatives of both Parties. No modification will be made by email communications.

 

		19.7	Severability

 

If any provision hereof is held to be invalid, illegal
or unenforceable in any jurisdiction, the Parties hereto shall negotiate in good faith a valid, legal and enforceable substitute
provision that most nearly reflects the original intent of the Parties, and all other provisions hereof shall remain in full force
and effect in such jurisdiction and shall be construed in order to carry out the intentions of the Parties hereto as nearly as
may be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such
other provisions in any other jurisdiction, so long as the essential essence of the Agreement remains enforceable.

 

		19.8	Third Party Beneficiaries

 

Nothing in the Agreement, express or implied, is intended
to confer any benefits, rights or remedies on any entity, other than the Parties and their permitted successors and assigns. However,
if there is a joint owner of any Patent Rights identified in Section 1 of the Patent License Agreement (other than Licensee), then
Licensee hereby agrees that the following provisions of these Terms and Conditions extend to the benefit of the co-owner identified
therein (excluding the Licensee to the extent it is a co-owner) as if such co-owner was identified in each reference to the Licensor:
the retained rights under clause (b) of Section 2.1; Section 11.3 (Licensor Disclaimers); Section 12 (Limitation of Liability);
Section 13 (Indemnification); Section 14.1 (Insurance Requirements); Section 17 (Use of Name); and Section 19.10 (Sovereign Immunity,
if applicable).

 

		19.9	Waiver

 

Neither Party will be deemed to have waived any of
its rights under the Agreement unless the waiver is in writing and signed by such Party. No delay or omission of a Party in exercising
or enforcing a right or remedy under the Agreement shall operate as a waiver thereof.

 

		19.10	Sovereign Immunity

 

Nothing in the Agreement shall be deemed or treated
as any waiver of Licensor’s sovereign immunity.

 

    	 	33	 

     

    

 

		19.11	Entire Agreement

 

The Agreement constitutes the entire Agreement between
the Parties regarding the subject matter hereof, and supersedes all prior written or verbal agreements, representations and understandings
relative to such matters.

 

		19.12	Claims Against Licensor for Breach of Agreement

 

Licensee acknowledges that any claim for breach of
the Agreement asserted by Licensee against Licensor shall be subject to Chapter 2260 of the Texas Government Code and that the
process provided therein shall be Licensee’s sole and exclusive process for seeking a remedy for any and all alleged breaches
of the Agreement by Licensor or the State of Texas.

 

		19.13	Grant of Security Interest

 

Licensee hereby grants to Licensor a security interest
in and to Licensee’s rights under the Patent License Agreement, as collateral security for the payment by Licensee of any
and all sums which may be owed from time to time by Licensee to Licensor. Licensor shall have all rights of a secured party as
specified in the Texas Uniform Commercial Code relative to this security interest and the enforcement thereof. Licensee hereby
authorizes Licensor to file with the appropriate governmental agencies appropriate UCC¬1 financing statements to evidence this
security interest.

 

— END OF EXHIBIT A —

 

    	 	34	 

     

    

 

EXHIBIT B

Exclusive Patent Rights

 

	App. No./

Date of Filing	Title	Inventor(s)	Jointly Owned? (Y/N; if 

Y, with whom?)	Prosecution Counsel
	
        Canada Serial No. 2,678,455

        Filed on 08/14/2009
	Enhanced Delivery of Immunosuppressive Drug Compositions for Pulmonary Delivery (5175 WIL)	
        Keith P. Johnston

        Jason T. McConville

        Jay I. Peters

        True L Rogers

        Prapasri Sinswat

        Robert L. Talbert Jr.

        Alan B. Watts

        Robert O. Williams III
	
         ̈ Yes, w/ The
        University of Texas Health Science Center at San Antionio

         ̈ No
	Parker Highlander
	
        Patent No. 2124898 Issued in Germany, Spain, and Europe.

        Filed on 08/06/2009
	Enhanced Delivery of Immunosuppressive Drug Compositions for Pulmonary Delivery (5175 WIL)	
        Keith P. Johnston

        Jason T. McConville

        Jay I. Peters

        True L Rogers

        Prapasri Sinswat

        Robert L. Talbert Jr.

        Alan B. Watts

        Robert O. Williams III
	
         ̈ Yes, w/ The
        University of Texas Health Science Center at San Antionio

         ̈ No
	Parker Highlander
	
        US National Serial No. 12/522,774

        Filed on 07/10/2009
	Enhanced Delivery of Immunosuppressive Drug Compositions for Pulmonary Delivery (5175 WIL)	
        Keith P. Johnston

        Jason T. McConville

        Jay I. Peters

        True L Rogers

        Prapasri Sinswat

        Robert L. Talbert Jr.

        Alan B. Watts

        Robert O. Williams III
	
         ̈ Yes, w/ The
        University of Texas Health Science Center at San Antionio

         ̈ No
	Parker Highlander

                                                                                 

 

    	 	35	 

     

    

 

	App. No./

Date of Filing	Title	Inventor(s)	Jointly Owned? (Y/N; if 

Y, with whom?)	Prosecution Counsel
	
        US Provisional Serial No. 60/884,383

        Filed on 1/10/2007
	Enhanced Delivery of Immunosuppressive Drug Compositions for Pulmonary Delivery (5175 WIL)	
        Keith P. Johnston

        Jason T. McConville

        Jay I. Peters

        True L Rogers

        Prapasri Sinswat

        Robert L. Talbert Jr.

        Alan B. Watts

        Robert O. Williams III
	
         ̈ Yes, w/ The
        University of Texas Health Science Center at San Antionio

         ̈ No
	Parker Highlander
	
        Serial No. 14/621,337

        Continuation of 12/522,774

        Filed on 02/12/2015
	Enhanced Delivery of Immunosuppressive Drug Compositions for Pulmonary Delivery (5175 WIL)	
        Keith P. Johnston

        Jason T. McConville

        Jay I. Peters

        True L Rogers

        Prapasri Sinswat

        Robert L. Talbert Jr.

        Alan B. Watts

        Robert O. Williams III
	
         ̈ Yes, w/ The
        University of Texas Health Science Center at San Antionio

         ̈ No
	Parker Highlander
	
        Serial No. 2124898

        Issued in France, and United Kingdom
	Enhanced Delivery of Immunosuppressive Drug Compositions for Pulmonary Delivery (5175 WIL)	
        Keith P. Johnston

        Jason T. McConville

        Jay I. Peters

        True L Rogers

        Prapasri Sinswat

        Robert L. Talbert Jr.

        Alan B. Watts

        Robert O. Williams III
	
         ̈ Yes, w/ The
        University of Texas Health Science Center at San Antionio

         ̈ No
	Parker Highlander

                                                                                 

 

    	 	36	 

     

    

 

	App. No./

Date of Filing	Title	Inventor(s)	Jointly Owned? (Y/N; if 

Y, with whom?)	Prosecution Counsel
	
        PCT/US2008/050795

        Filed on 01/10/2008
	Enhanced Delivery of Immunosuppressive Drug Compositions for Pulmonary Delivery (5175 WIL)	
        Keith P. Johnston

        Jason T. McConville

        Jay I. Peters

        True L Rogers

        Prapasri Sinswat

        Robert L. Talbert Jr.

        Alan B. Watts

        Robert O. Williams III
	
         ̈ Yes, w/ The
        University of Texas Health Science Center at San Antionio

         ̈ No
	Parker Highlander
	
        US Serial No. 11/660,012

        Filed on 08/15/2007
	Enhanced Delivery of Immunosuppressive Drug Compositions for Pulmonary Delivery (2802 WIL)	
        Robert O. Williams III

        Keith P. Johnston

        Jason T. McConville

        Robert L. Talbert Jr.

        David S. Burgess

        Jay I. Peters

        Brian D. Scherzer

        Christopher J. Tucker

        David A. Hayes

        Ian B. Gilespie

        James E. Hitt

        Nicholas S. Beck

        Paula C. Garcia

        True L Rogers

        Timothy J. Young
	
         ̈ Yes, w/ The
        University of Texas Health Science Center at San Antionio

        Also subject to INT-27237603 with DOW

         ̈ No
	Parker Highlander

                                                                                 

 

    	 	37	 

     

    

 

	App. No./

Date of Filing	Title	Inventor(s)	Jointly Owned? (Y/N; if 

Y, with whom?)	Prosecution Counsel
	
        US Serial No. 17/713,156

        Continuation of 11/660,012

        Filed on 05/15/2015
	Enhanced Delivery of Immunosuppressive Drug Compositions for Pulmonary Delivery (2802 WIL)	
        James E. Hitt

        True L Rogers

        Brian D. Scherzer

        Ian B. Gilespie

        Paula C. Garcia

        Nicholas S. Beck

        Christopher J. Tucker

        Timothy J. Young

        David A. Hayes

        Robert O. Williams III

        Keith P. Johnston

        Jason T. McConville

        Jay I. Peters

        Robert L. Talbert Jr.

        David S. Burgess
	
         ̈ Yes, w/ The
        University of Texas Health Science Center at San Antionio

        Also subject to INT-27237603 with DOW

         ̈ No
	Parker Highlander
	PCT/US52005/030543	Enhanced Delivery of Immunosuppressive Drug Compositions for Pulmonary Delivery (2802 WIL)	
        Robert O. Williams III

        Keith P. Johnston

        Jason T. McConville

        Robert L. Talbert Jr.

        David S. Burgess

        Jay I. Peters

        Brian D. Scherzer

        Christopher J. Tucker

        David A. Hayes

        Ian B. Gilespie

        James E. Hitt

        Nicholas S. Beck

        Paula C. Garcia

        True L Rogers

        Timothy J. Young
	
         ̈ Yes, w/ The
        University of Texas Health Science Center at San Antionio

        Also subject to INT-27237603 with DOW

         ̈ No
	Parker Highlander

                                                                                 

 

    	 	38	 

     

    

 

	App. No./

Date of Filing	Title	Inventor(s)	Jointly Owned? (Y/N; if 

Y, with whom?)	Prosecution Counsel
	
        US Provisional Serial No. 60/605,179

        Filed on 8/27/2004
	Enhanced Delivery of Immunosuppressive Drug Compositions for Pulmonary Delivery (2802 WIL)	
        Robert O. Williams III

        Keith P. Johnston

        Jason T. McConville
	
         ̈

         ̈ No

        Also subject to INT-27237603 with DOW
	Parker Highlander
	
        US Serial No. 12/778,795

        Filed on 05/12/2010

        Continuation in Part of US Serial No. 12/371,573 Filed on 02/13/2009
	Compositions and Methods of Making Brittle-Matrix Particles Through Blister Pack Freezing (5408 JOH)	
        Keith P. Johnston

        Jasmine Tam (Rowe)

        Alan B. Watts

        Joshua Engstrom

        (A petition was filed to add Robert O. Williams III)
	
         ̈

         ̈ No
	Parker Highlander
	
        US Serial No. 10/639,361

        Filed on 08/12/2003
	Process for Production of Nanoparticles and Microparticles by Spray Freezing Into Liquid (5612 DOW)	
        Brian D. Scherzer

        Jonathan C. Evans

        James E. Hitt
	
         ̈ Yes,

         ̈ No, IP was
        assigned from DOW to The Board of Regents of The University of Texas per INT-27237603
	Parker Highlander
	
        Patent No. 4933732 Issued in Japan

        Filed on 08/12/2003
	Drug Particles From Freezing onto a Surface (5612 DOW)	
        Brian D. Scherzer

        Jonathan C. Evans

        James E. Hitt
	
         ̈ Yes,

         ̈ No, IP was
        assigned from DOW to The Board of Regents of The University of Texas per INT-27237603
	Parker Highlander

                                                                                 

 

    	 	39	 

     

    

 

	App. No./

Date of Filing	Title	Inventor(s)	Jointly Owned? (Y/N; if 

Y, with whom?)	Prosecution Counsel
	
        Patent No. 112782 Issued in Singapore

        Filed on 08/12/2003
	Drug Particles From Freezing onto a Surface (5612 DOW)	
        Brian D. Scherzer

        Jonathan C. Evans

        James E. Hitt
	
         ̈ Yes,

         ̈ No, IP was
        assigned from DOW to The Board of Regents of The University of Texas per INT-27237603
	Parker Highlander
	
        PCT/US2003/025338

        Filed on 08/12/2003
	Drug Particles From Freezing onto a Surface (5612 DOW)	
        Brian D. Scherzer

        Jonathan C. Evans

        James E. Hitt
	
         ̈ Yes,

         ̈ No, IP was
        assigned from DOW to The Board of Regents of The University of Texas per INT-27237603
	Parker Highlander
	
        US Serial No. 62/156,052

        Filed on 5/1/2015
	
        Multidrug Brittle Matrix Compositions

        (6677 WIL and 6678 WIL)
	
        Robert O. Williams III

        Alan B. Watts

        Jay I. Peters
	
         ̈ Yes, working
        with UTHSC-SA to get IIA in place

         ̈
	Parker Highlander
	
        US Serial No. 12/371,573

        Filed on 2/13/2009
	
        Templated Open Flocs of Anisotropic Particles for Enhanced Pulmonary
        Delivery

        (5312 JOH)
	
        Joshua Engstrom

        Keith P. Johnston

        Jasmine Tam (Rowe)

        Robert O. Williams
	
         ̈ Yes,

         ̈ No
	Parker Highlander
	
        Canada Serial No. 2,723,314

        Filed on 2/13/2009
	
        Templated Open Flocs of Anisotropic Particles for Enhanced Pulmonary
        Delivery

        (5312 JOH)
	
        Joshua Engstrom

        Keith P. Johnston

        Jasmine Tam (Rowe)

        Robert O. Williams
	
         ̈ Yes,

         ̈ No
	Parker Highlander
	
        Australia Issued Patent No. 2009214443

        Filed on 2/13/2009
	
        Templated Open Flocs of Anisotropic Particles for Enhanced Pulmonary
        Delivery

        (5312 JOH)
	
        Joshua Engstrom

        Keith P. Johnston

        Jasmine Tam (Rowe)

        Robert O. Williams
	
         ̈ Yes,

         ̈ No
	Parker Highlander

                                                                                 

 

    	 	40	 

     

    

 

	App. No./

Date of Filing	Title	Inventor(s)	Jointly Owned? (Y/N; if 

Y, with whom?)	Prosecution Counsel
	
        Europe Serial No. 09709833.9

        Filed on 9/13/2010
	
        Templated Open Flocs of Anisotropic Particles for Enhanced Pulmonary
        Delivery

        (5312 JOH)
	
        Joshua Engstrom

        Keith P. Johnston

        Jasmine Tam (Rowe)

        Robert O. Williams
	
         ̈ Yes,

         ̈ No
	Parker Highlander
	
        US Serial No. 61/028,218

        Filed on 2/13/2008
	
        Non-Settling Flocs for Surfactant-Free Enhanced Pulmonary Delivery
        with Pressurized Metered Dose Inhalers

        (5312 JOH)
	
        Joshua Engstrom

        Keith P. Johnston

        Jasmine Tam (Rowe)

        Robert O. Williams
	
         ̈ Yes,

         ̈ No
	Parker Highlander
	
        PCT/US2009/034162

        Filed on 2/13/2009
	
        Tern plated Open Flocs of Anisotropic Particles for Enhanced
        Pulmonary Delivery

        (5312 JOH)
	
        Joshua Engstrom

        Keith P. Johnston

        Jasmine Tam (Rowe)

        Robert O. Williams
	
         ̈ Yes,

         ̈ No
	Parker Highlander

 

    	 	41	 

     

    

 

EXHIBIT C

Limited Exclusive Patent Rights

 

	App. No./

Date of Filing	Title	Inventor(s)	Jointly Owned? (Y/N; if 

Y, with whom?)	Prosecution Counsel
	US Divisional Instructed on 01/13/14	Formation of Stable Submicron Peptide or Protein Particles by Thin Film Freezing (5254 JOH)	
        Keith P. Johnston

        Joshua Engstrom

        Robert O. Williams
	
         ̈ Yes,

         ̈ No
	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	
        Europe Serial No. 08771657.7

        Filed on 01/22/2010
	Formation of Stable Submicron Peptide or Protein Particles by Thin Film Freezing (5254 JOH)	
        Keith P. Johnston

        Joshua Engstrom

        Robert O. Williams
	
         ̈ Yes,

         ̈ No
	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	
        US Serial No. 12/665,386

        Issued US Patent No. 8,968,786

        Filed on 12/18/2009
	Formation of Stable Submicron Peptide or Protein Particles by Thin Film Freezing (5254 JOH)	
        Keith P. Johnston

        Joshua Engstrom

        Robert O. Williams
	
         ̈ Yes,

         ̈ No
	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	
        Serial No. 14/603,211

        Filed on 01/22/2015

        Divisional of US Serial No. 12/665,386

        Filed on 12/18/2009
	Formation of Stable Submicron Peptide or Protein Particles by Thin Film Freezing (5254 JOH)	
        Keith P. Johnston

        Joshua Engstrom

        Robert O. Williams
	
         ̈ Yes,

         ̈ No
	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	
        US Provisional Serial No. 60/945,737

        Filed on 6/22/2007
	Formation of Stable Submicron Peptide or Protein Particles by Thin Film Freezing (5254 JOH)	
        Keith P. Johnston

        Joshua Engstrom
	
         ̈ Yes,

         ̈ No
	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	
        Canada Serial No. 2,691,531

        Filed on 12/22/2009
	Formation of Stable Submicron Peptide or Protein Particles by Thin Film Freezing (5254 JOH)	
        Keith P. Johnston

        Joshua Engstrom
	
         ̈ Yes,

         ̈ No
	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	
        Japan Serial No. 2010-513468

        Filed on 02/19/2010
	Formation of Stable Submicron Peptide or Protein Particles by Thin Film Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Freezing (5254 JOH)	
        Keith P. Johnston

        Joshua Engstrom
	
         ̈ Yes,

         ̈ No
	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

                                                                                 

 

    	 	42	 

     

    

	App. No./

Date of Filing	Title	Inventor(s)	Jointly Owned? (Y/N; if 

Y, with whom?)	Prosecution Counsel
	
        PCT/US2008/067766

        Filed on 06/20/2008
	Formation of Stable Submicron Peptide or Protein Particles by Thin Film Freezing (5254 JOH)	
        Keith P. Johnston

        Joshua Engstrom
	
         ̈ Yes,

         ̈ No
	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

 

    	 	43

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]